U.S. Markets closed
LISTEN

Schultz: Businesses need to do more to help people

Yahoo Finance's Julia La Roche sits down with executive chairman and former CEO of Starbucks Howard Schultz

Taxus Cardium Pharmaceuticals Group, Inc. (CRXM)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.151140.00000 (0.00000%)
At close: 3:54PM EDT
People also watch
FPMIRIHTBTHEAOLSCRYO
Full screen
Previous Close0.15114
Open0.12000
Bid0.00000 x 0
Ask0.00000 x 0
Day's Range0.12000 - 0.15114
52 Week Range0.01000 - 0.29000
Volume902
Avg. Volume6,342
Market Cap2.17M
Beta-0.12
PE Ratio (TTM)-0.53
EPS (TTM)-0.28
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
Trade prices are not sourced from all markets
  • PR Newswire3 months ago

    Excellagen® Receives USPTO Notice Of Allowance For A New Patent Application Covering Blood Platelet Activation & Endogeneous Growth Factor Release For Wound Repair And Tissue Regeneration

    SAN DIEGO, June 13, 2017 /PRNewswire/ -- Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) and its operating unit Activation Therapeutics today announced that a Notice of Allowance has been ...

  • PR Newswire3 months ago

    Angionetics To Present At Marcum 2017 MicroCap conference In New York City

    SAN DIEGO, June 12, 2017 /PRNewswire/ -- Angionetics Inc., a majority-owned subsidiary of Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM), focused on the discovery, clinical and commercial development of Generx [Ad5FGF-4] cardiovascular and cerebral angiogenic gene therapy, today announced that Mr. Christopher J. Reinhard, its Chief Executive Officer, will be presenting at the Marcum 2017 MicroCap Conference in New York City on June 16, 2017. Angionetics is a biotechnology company, recently-formed by Taxus Cardium, that has been designed to affect an asset "value unlock" of its undervalued technology platforms.  As Angionetics advances forward with its plan to operate as a company independent of Taxus Cardium, it will focus on the clinical and commercial development of angiogenic, gene- based bio-therapeutics for the treatment of up to an estimated 1.2 million patients in the U.S. who have late-stage coronary artery disease and refractory angina, as well as other medical conditions due to myocardial ischemia.

  • PR Newswire4 months ago

    Angionetics To Present At Globalization Of Research And Industrialization Of Bio-Medicine Summit 2017 In Shenzhen, China

    SAN DIEGO, June 5, 2017 /PRNewswire/ -- Angionetics Inc., a majority-owned subsidiary of Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM), focused on the Phase 3 clinical development of Generx [Ad5FGF-4] cardiovascular and cerebral angiogenic gene therapy, today announced that Mr. Christopher J. Reinhard, its Chief Executive Officer, will be presenting at the Globalization of Research and Industrialization Summit 2017 in Shenzhen, China on June 6, 2017. Angionetics is a biotechnology company, recently formed by Taxus Cardium, that has been designed to affect an asset "value unlock" of its undervalued technology platforms.  As Angionetics advances forward with its plan to operate as a company independent of Taxus Cardium, it will focus on the clinical and commercial development of angiogenic, gene-based bio-therapeutics for the treatment of up to an estimated 1.2 million patients in the U.S. who have late-stage coronary artery disease and refractory angina, as well as other medical conditions due to myocardial ischemia.